Ergoteles’s OptimizeRx OPRX Stock Holding History

Ergoteles’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-40,996	Closed	-$600K	–	1378
2023 Q1	$600K	Buy	40,996 +23,213	+131%	+$388K	0.02%	673
2022 Q4	$299K	Buy	+17,783	New	+$308K	0.01%	912
2021 Q4	–	Sell	-4,400	Closed	-$376K	–	1495
2021 Q3	$376K	Buy	+4,400	New	+$276K	0.01%	703

Other funds holding OPRX

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Ergoteles's OPRX Position: Q2 2023 in Review

Ergoteles sold out of OptimizeRx (OPRX) in Q2 2023, closing a stake of 40,996 shares — an estimated $600K sold.

Ergoteles first reported a position in OPRX in Q3 2021 and held it in 3 quarters. The position peaked at $600K in Q1 2023. 102 funds tracked by Wall St. Rank hold OPRX as of Q2 2023.

Ergoteles reported no remaining OptimizeRx position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 40,996 OptimizeRx shares in Q2 2023, an estimated $600K.
Ergoteles first reported a position in OptimizeRx in Q3 2021 and held it in 3 quarters.
Ergoteles's OptimizeRx position peaked at $600K in Q1 2023.
102 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.